Major Depressive Disorder
Conditions
Brief summary
The purpose of this study is to evaluate the efficacy and safety of AGN-241751 in participants with Major Depressive Disorder
Interventions
DRUGAGN-241751
AGN-241751 is supplied in tablet form
DRUGPlacebo
Placebo is supplied in tablet form
Sponsors
Syndeio Biosciences, Inc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Written informed consent from the participant has been obtained prior to any study-related procedures * Meet DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) criteria (American Psychiatric Association, 2013). for MDD (based on confirmation from the modified SCID), with a current major depressive episode of at least 8 weeks and not exceeding 18 months in duration at Visit 1. * Have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test at screening (Visit 1) if a WOCBP (Women of Childbearing Potential). * Female participants willing to minimize the risk of becoming pregnancy for the duration of the clinical study and follow-up period. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: * Not a WOCBP (Women of Childbearing Potential). OR * A WOCBP (Women of Childbearing Potential). who agrees to follow the contraceptive guidance in during the treatment period and for at least 4 to 5 weeks after the last dose of study treatment. * Male participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period. A male participant must agree to use contraception during the treatment period and for at least 10 weeks after the last dose of study treatment and refrain from donating sperm during this period. * Able, as assessed by the investigator, and willing to follow study instructions and likely to complete all required study visits.
Exclusion criteria
Psychiatric and Treatment-Related Criteria * DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) based diagnosis of any disorder other than MDD that was the primary focus of treatment within 6 months before Visit 1. Comorbid generalized anxiety disorder, social anxiety disorder, or specific phobias are acceptable provided they play a secondary role in the balance of symptoms and are not the primary driver of treatment decisions. * Lifetime history of meeting DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition)criteria for: * Schizophrenia spectrum or other psychotic disorder * Bipolar or related disorder * Major neurocognitive disorder * Neurodevelopmental disorder of greater than mild severity or of a severity that impacts the participant's ability to consent, follow study directions, or otherwise safely participate in the study * Dissociative disorder * Posttraumatic stress disorder * MDD with psychotic features * History of meeting DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) criteria for alcohol or substance use disorder (other than nicotine or caffeine) within the 6 months before Screening (Visit 1). * History (based on participant report and/or medical records, and investigator judgment) of the following: * Inadequate response to ECT, a monoamine oxidase inhibitor, ketamine, or adjunctive treatment with an antipsychotic * Treatment with clozapine or any depot antipsychotic * ECT, vagus nerve stimulation, transcranial magnetic stimulation, or any experimental central nervous system treatment during the current episode or in the 6 months before Screening (Visit 1) whichever is longer) * Tardive dyskinesia, serotonin syndrome, or neuroleptic malignant syndrome * Having received: * Anticonvulsant/mood stabilizer, within 1 year prior to Screening (Visit 1) * Antipsychotic in the current episode, with the exception of quetiapine given for insomnia ≤ 50 mg/day provided it can be safely discontinued prior to Visit 2 * Combination therapy of more than 2 ADTs in the current episode if given for depression at adequate dose and duration * ADT augmentation agent in the current episode * Lifetime history of nonresponse to ≥ 2 antidepressants after adequate trials (adequate treatment is defined as at least 6 weeks at an adequate dose(s) based on approved package insert recommendations). * Positive result at Screening (Visit 1) from the UDS (Urine Drug Screen) test for any prohibited medication. Exception: Participants with a positive UDS (Urine Drug Screen) at Screening for opiates, cannabinoids, or episodic use of benzodiazepines may be allowed in the study provided: * The drug was used for a legitimate medical purpose; * The drug can be safely discontinued prior to participation in the study (except for episodic use of benzodiazepines which may be continued); and * A repeat UDS is negative for these substances prior to enrollment (except for episodic use of benzodiazepines which may be continued) * Part B participants who have regularly been using benzodiazepines (even for legitimate medical purposes) for more than 2 months should not be included in the study if there is doubt that the medication can be safely discontinued during screening. * A suicide attempt within the past year * Prior participation in any investigational study of AGN-241751 * Initiation or termination of psychotherapy for depression within the 3 months preceding Screening (Visit 1), or plans to initiate, terminate, or change such therapy during the course of the study. (Support meetings or counseling \[eg, marital counseling\] are allowed provided they are no more frequent than weekly and do not have treatment of depression as their objective.) * Ongoing treatment with phototherapy, or termination of phototherapy within 1 month of Visit 1. * Known allergy or sensitivity to the study medication or its components. * Hypothyroidism or hyperthyroidism, unless stabilized on appropriate pharmacotherapy with no change in dosage for at least 1 month before Screening (Visit 1) * History of seizure disorder, stroke, significant head injury, tumor of the central nervous system, or any other condition that predisposes to seizure. * Known HIV infection * Part B: Previously diagnosed hearing loss; current hearing aid users (within the last 6 months), or history of gross hearing loss, such as conductive hearing loss, congenital hearing loss, sudden hearing loss, hearing loss due to recent noise or occupational exposure. * Current enrollment in an investigational drug or device study or participation in such a study within 6 months of entry into this study (or within 3 months of entry into this study (Part B). * Part B: Prior participation in any investigational study of AGN-241751, rapastinel, ketamine, or esketamine. Part B participants should not have participated in Part A at any time, and Part A participants should not have participated in Part B at any time (ie, Part A is not a contingent step to participate in Part B). * Employee, or immediate relative of an employee, of the sponsor, any of its affiliates or partners, or the study center * Inability to speak, read, and understand the English language sufficiently to understand the nature of the study, to provide written informed consent, or to allow the completion of all study assessments.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group | Baseline (Day1) to Day 2 | Efficacy will be measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement. Results are reported as change from baseline in treated group compared to change from baseline in placebo, reported as least squares difference and (standard error) calculated from a mixed model-repeated measures analysis |
| Part B: Change From Baseline in MADRS Score at Day 8 Post the Initial Dose of AGN-241751 (i.e. 1 Day After the Seventh Daily Dose) | Baseline (Day 1) to Day 8 | Efficacy was measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part A: Change From Baseline in MADRS Score on Day 9 and Day 15 of AGN-241751 Once Daily and at Day 22 (7 Days After Completion of AGN-241751 Dosing) Compared With Change in Placebo | Baseline (Day 1) to Day 22 | Efficacy was measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement. |
| Part B: Change From Baseline in MADRS Score on Day 11, Day 14, and Day 18 of AGN-241751 Administered Two Times Daily and on Day 21 (7 Days After Completion of Dosing) in Treated Group Compared to Change From Baseline in Placebo Group | Baseline (Day 1) to Day 21 | Efficacy was measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement. Results are reported as change from baseline in treated group compared to change from baseline in placebo, reported as least squares difference and (standard error) calculated from a mixed model-repeated measures analysis |
Countries
United States
Contacts
STUDY_DIRECTORRonald M Burch, MD PhD
Syndeio Biosciences, Inc
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| AGN-241751 3mg Daily AGN-241751, oral administration, once per day in Part A.
AGN-241751: AGN-241751 is supplied in tablet form | 26 |
| AGN-241751 10mg Daily AGN-241751, oral administration, once per day in Part A.
AGN-241751: AGN-241751 is supplied in tablet form | 26 |
| AGN-241751 25mg Daily AGN-241751, oral administration, once per day in Part A.
AGN-241751: AGN-241751 is supplied in tablet form | 26 |
| Placebo Daily Placebo, oral administration, once per day in part A.
Placebo: Placebo is supplied in tablet form | 25 |
| AGN-241751 3mg Two Times Per Day AGN-241751, oral administration, BID in Part B.
AGN-241751: AGN-241751 is supplied in tablet form | 40 |
| AGN-241751 25mg Two Times Per Day AGN-241751, oral administration, BID in Part B.
AGN-241751: AGN-241751 is supplied in tablet form | 40 |
| Placebo 2 Times Per Day Placebo, oral administration, two times per day in part B.
Placebo: Placebo is supplied in tablet form | 41 |
| Total | 224 |
Baseline characteristics
| Characteristic | AGN-241751 3mg Daily | AGN-241751 10mg Daily | AGN-241751 25mg Daily | Placebo Daily | AGN-241751 3mg Two Times Per Day | AGN-241751 25mg Two Times Per Day | Placebo 2 Times Per Day | Total |
|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 44.2 years STANDARD_DEVIATION 13.14 | 39.0 years STANDARD_DEVIATION 13.84 | 41.4 years STANDARD_DEVIATION 15.03 | 36.2 years STANDARD_DEVIATION 12.43 | 38.5 years STANDARD_DEVIATION 12.62 | 40.3 years STANDARD_DEVIATION 14.21 | 37.7 years STANDARD_DEVIATION 14.06 | 40.2 years STANDARD_DEVIATION 13.78 |
| Montgomery-Asberg Depression Severity (MADRS) score at baseline (prior to first dose) | 34.0 units on a scale STANDARD_DEVIATION 4.48 | 35.0 units on a scale STANDARD_DEVIATION 4.51 | 33.3 units on a scale STANDARD_DEVIATION 5.02 | 34.0 units on a scale STANDARD_DEVIATION 4.2 | 34.1 units on a scale STANDARD_DEVIATION 3.62 | 34.2 units on a scale STANDARD_DEVIATION 4.12 | 33.8 units on a scale STANDARD_DEVIATION 5.05 | 34.06 units on a scale STANDARD_DEVIATION 0.509 |
| Race/Ethnicity, Customized American Indian or Alaska Native | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized Asian | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 3 Participants | 5 Participants |
| Race/Ethnicity, Customized Black | 9 Participants | 11 Participants | 7 Participants | 8 Participants | 25 Participants | 22 Participants | 26 Participants | 108 Participants |
| Race/Ethnicity, Customized Missing | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Multiple | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 3 Participants | 1 Participants | 0 Participants | 4 Participants |
| Race/Ethnicity, Customized Native Hawaiian or Pacific Islander | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized White | 16 Participants | 14 Participants | 18 Participants | 15 Participants | 12 Participants | 16 Participants | 12 Participants | 103 Participants |
| Region of Enrollment United States | 26 participants | 26 participants | 26 participants | 25 participants | 40 participants | 40 participants | 41 participants | 224 participants |
| Sex: Female, Male Part A Female | 18 Participants | 16 Participants | 18 Participants | 14 Participants | 20 Participants | 14 Participants | 12 Participants | 112 Participants |
| Sex: Female, Male Part A Male | 8 Participants | 10 Participants | 8 Participants | 11 Participants | 20 Participants | 26 Participants | 29 Participants | 112 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk |
|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 26 | 0 / 26 | 0 / 26 | 0 / 25 | 0 / 41 | 0 / 41 | 0 / 41 |
| other Total, other adverse events | 6 / 26 | 8 / 26 | 6 / 26 | 3 / 25 | 15 / 41 | 20 / 41 | 22 / 41 |
| serious Total, serious adverse events | 0 / 26 | 0 / 26 | 0 / 26 | 0 / 25 | 0 / 41 | 0 / 41 | 1 / 41 |
Outcome results
Primary
Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group
Efficacy will be measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement. Results are reported as change from baseline in treated group compared to change from baseline in placebo, reported as least squares difference and (standard error) calculated from a mixed model-repeated measures analysis
Time frame: Baseline (Day1) to Day 2
Population: Modified Intent-to-Treat
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| AGN-241751 3mg Daily | Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group | -9.4 score on a scale | Standard Error 1.57 |
| AGN-241751 10mg Daily | Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group | -6.7 score on a scale | Standard Error 1.58 |
| AGN-241751 25mg Daily | Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group | -9.5 score on a scale | Standard Error 1.57 |
| Placebo Daily | Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group | -9.3 score on a scale | Standard Error 1.61 |
Comparison: Change from baseline in treated group compared to change from baseline in placebo group on Day 2 (Day 1 post initial dose). Since this was a phase 1 study no power calculation was performed.p-value: 0.98Mixed Models Analysis
Comparison: Change from baseline in treated group compared to change from baseline in placebo group on Day 2 (Day 1 post initial dose). Since this was a phase 1 study no power calculation was performed.p-value: 0.25Mixed Models Analysis
Comparison: Change from baseline in treated group compared to change from baseline in placebo group on Day 2 (Day 1 post initial dose).p-value: 0.93Mixed Models Analysis
Primary
Part B: Change From Baseline in MADRS Score at Day 8 Post the Initial Dose of AGN-241751 (i.e. 1 Day After the Seventh Daily Dose)
Efficacy was measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement.
Time frame: Baseline (Day 1) to Day 8
Population: Modified Intent-to-Treat, subjects who completed Day 8 assessments
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| AGN-241751 3mg Two Times Per Day | Part B: Change From Baseline in MADRS Score at Day 8 Post the Initial Dose of AGN-241751 (i.e. 1 Day After the Seventh Daily Dose) | -12.8 score on a scale | Standard Error 1.53 |
| AGN-241751 25mg Two Times Per Day | Part B: Change From Baseline in MADRS Score at Day 8 Post the Initial Dose of AGN-241751 (i.e. 1 Day After the Seventh Daily Dose) | -10.5 score on a scale | Standard Error 1.52 |
| Placebo 2 Times Per Day | Part B: Change From Baseline in MADRS Score at Day 8 Post the Initial Dose of AGN-241751 (i.e. 1 Day After the Seventh Daily Dose) | -10.9 score on a scale | Standard Error 1.48 |
Comparison: Chane from baseline in treated group compared to change from baseline in placebo group. Since this was a phase 1 study no power calculation was performed. Statistical tests were 2-sided hypothesis tests performed at the 5% level of significance.p-value: 0.43Mixed Models Analysis
Comparison: Change from baseline in treated group compared to change in placebo group. Since this was a phase 1 study no power calculation was performed. Statistical tests were 2-sided hypothesis tests performed at the 5% level of significance.p-value: 0.84Mixed Models Analysis
Secondary
Part A: Change From Baseline in MADRS Score on Day 9 and Day 15 of AGN-241751 Once Daily and at Day 22 (7 Days After Completion of AGN-241751 Dosing) Compared With Change in Placebo
Efficacy was measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement.
Time frame: Baseline (Day 1) to Day 22
Population: Modified Intent-to-Treat
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| AGN-241751 3mg Daily | Part A: Change From Baseline in MADRS Score on Day 9 and Day 15 of AGN-241751 Once Daily and at Day 22 (7 Days After Completion of AGN-241751 Dosing) Compared With Change in Placebo | Day 9 | -13.0 score on a scale | Standard Error 1.86 |
| AGN-241751 3mg Daily | Part A: Change From Baseline in MADRS Score on Day 9 and Day 15 of AGN-241751 Once Daily and at Day 22 (7 Days After Completion of AGN-241751 Dosing) Compared With Change in Placebo | Day 22 | -12.5 score on a scale | Standard Error 1.97 |
| AGN-241751 3mg Daily | Part A: Change From Baseline in MADRS Score on Day 9 and Day 15 of AGN-241751 Once Daily and at Day 22 (7 Days After Completion of AGN-241751 Dosing) Compared With Change in Placebo | Day 15 | -13.2 score on a scale | Standard Error 1.86 |
| AGN-241751 10mg Daily | Part A: Change From Baseline in MADRS Score on Day 9 and Day 15 of AGN-241751 Once Daily and at Day 22 (7 Days After Completion of AGN-241751 Dosing) Compared With Change in Placebo | Day 9 | -13.6 score on a scale | Standard Error 1.87 |
| AGN-241751 10mg Daily | Part A: Change From Baseline in MADRS Score on Day 9 and Day 15 of AGN-241751 Once Daily and at Day 22 (7 Days After Completion of AGN-241751 Dosing) Compared With Change in Placebo | Day 22 | -11.8 score on a scale | Standard Error 1.91 |
| AGN-241751 10mg Daily | Part A: Change From Baseline in MADRS Score on Day 9 and Day 15 of AGN-241751 Once Daily and at Day 22 (7 Days After Completion of AGN-241751 Dosing) Compared With Change in Placebo | Day 15 | -13.7 score on a scale | Standard Error 1.87 |
| AGN-241751 25mg Daily | Part A: Change From Baseline in MADRS Score on Day 9 and Day 15 of AGN-241751 Once Daily and at Day 22 (7 Days After Completion of AGN-241751 Dosing) Compared With Change in Placebo | Day 15 | -13.2 score on a scale | Standard Error 1.89 |
| AGN-241751 25mg Daily | Part A: Change From Baseline in MADRS Score on Day 9 and Day 15 of AGN-241751 Once Daily and at Day 22 (7 Days After Completion of AGN-241751 Dosing) Compared With Change in Placebo | Day 9 | -14.1 score on a scale | Standard Error 1.85 |
| AGN-241751 25mg Daily | Part A: Change From Baseline in MADRS Score on Day 9 and Day 15 of AGN-241751 Once Daily and at Day 22 (7 Days After Completion of AGN-241751 Dosing) Compared With Change in Placebo | Day 22 | -14.5 score on a scale | Standard Error 1.9 |
| Placebo Daily | Part A: Change From Baseline in MADRS Score on Day 9 and Day 15 of AGN-241751 Once Daily and at Day 22 (7 Days After Completion of AGN-241751 Dosing) Compared With Change in Placebo | Day 9 | -12.0 score on a scale | Standard Error 1.89 |
| Placebo Daily | Part A: Change From Baseline in MADRS Score on Day 9 and Day 15 of AGN-241751 Once Daily and at Day 22 (7 Days After Completion of AGN-241751 Dosing) Compared With Change in Placebo | Day 22 | -13.6 score on a scale | Standard Error 1.94 |
| Placebo Daily | Part A: Change From Baseline in MADRS Score on Day 9 and Day 15 of AGN-241751 Once Daily and at Day 22 (7 Days After Completion of AGN-241751 Dosing) Compared With Change in Placebo | Day 15 | -11.6 score on a scale | Standard Error 1.9 |
Comparison: Change in MADRS score in treated groups compared to placebo group on Day 9. Since this was a phase 1 study no power calculation was performed. Statistical tests were 2-sided hypothesis tests performed at the 5% level of significance.p-value: 0.69Mixed Models Analysis
Comparison: Change in MADRS score in treated groups compared to placebo group on Day 9. Since this was a phase 1 study no power calculation was performed. Statistical tests were 2-sided hypothesis tests performed at the 5% level of significance.p-value: 0.44Mixed Models Analysis
Comparison: Change in MADRS score in treated groups compared to placebo group on Day 9. Since this was a phase 1 study no power calculation was performed. Statistical tests were 2-sided hypothesis tests performed at the 5% level of significance.p-value: 0.43Mixed Models Analysis
Comparison: Change in MADRS score in treated groups compared to placebo group on Day 15. Since this was a phase 1 study no power calculaton was performed. Statistical tests were 2-sided hypothesis tests performed at the 5% level of significance.p-value: 0.55Mixed Models Analysis
Comparison: Change in MADRS score in treated groups compared to placebo group on Day 15. Since this was a phase 1 study no power calculation was performed. Statistical tests were 2-sided hypothesis tests performed at the 5% level of significance.p-value: 0.44Mixed Models Analysis
Comparison: Change in MADRS score in treated groups compared to placebo group on Day 15. Since this was a phase 1 study no power calculation was performed. Statistical tests were 2-sided hypothesis tests performed at the 5% level of significance.p-value: 0.56Mixed Models Analysis
Comparison: Change in MADRS score in treated groups compared to placebo group on Day 22. Since this was a phase 1 study no power calculation was performed. Statistical tests were 2-sided hypothesis tests performed at the 5% level of significance.p-value: 0.8Mixed Models Analysis
Comparison: Change in MADRS score in treated groups compared to placebo group on Day 22. Since this was a phase 1 study no power calculation was performed. Statistical tests were 2-sided hypothesis tests performed at the 5% level of significance.p-value: 0.45Mixed Models Analysis
Comparison: Change in MADRS score in treated groups compared to placebo group on Day 22. Since this was a phase 1 study no power calculation was performed. Statistical tests were 2-sided hypothesis tests performed at the 5% level of significance.p-value: 0.67Mixed Models Analysis
Secondary
Part B: Change From Baseline in MADRS Score on Day 11, Day 14, and Day 18 of AGN-241751 Administered Two Times Daily and on Day 21 (7 Days After Completion of Dosing) in Treated Group Compared to Change From Baseline in Placebo Group
Efficacy was measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement. Results are reported as change from baseline in treated group compared to change from baseline in placebo, reported as least squares difference and (standard error) calculated from a mixed model-repeated measures analysis
Time frame: Baseline (Day 1) to Day 21
Population: Modified Intent to Treat
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| AGN-241751 3mg Two Times Per Day | Part B: Change From Baseline in MADRS Score on Day 11, Day 14, and Day 18 of AGN-241751 Administered Two Times Daily and on Day 21 (7 Days After Completion of Dosing) in Treated Group Compared to Change From Baseline in Placebo Group | Day 14 | -17.0 score on a scale | Standard Error 1.76 |
| AGN-241751 3mg Two Times Per Day | Part B: Change From Baseline in MADRS Score on Day 11, Day 14, and Day 18 of AGN-241751 Administered Two Times Daily and on Day 21 (7 Days After Completion of Dosing) in Treated Group Compared to Change From Baseline in Placebo Group | Day 21 | -17.3 score on a scale | Standard Error 1.79 |
| AGN-241751 3mg Two Times Per Day | Part B: Change From Baseline in MADRS Score on Day 11, Day 14, and Day 18 of AGN-241751 Administered Two Times Daily and on Day 21 (7 Days After Completion of Dosing) in Treated Group Compared to Change From Baseline in Placebo Group | Day 18 | -18.3 score on a scale | Standard Error 1.88 |
| AGN-241751 3mg Two Times Per Day | Part B: Change From Baseline in MADRS Score on Day 11, Day 14, and Day 18 of AGN-241751 Administered Two Times Daily and on Day 21 (7 Days After Completion of Dosing) in Treated Group Compared to Change From Baseline in Placebo Group | Day 11 | -15.8 score on a scale | Standard Error 1.7 |
| AGN-241751 25mg Two Times Per Day | Part B: Change From Baseline in MADRS Score on Day 11, Day 14, and Day 18 of AGN-241751 Administered Two Times Daily and on Day 21 (7 Days After Completion of Dosing) in Treated Group Compared to Change From Baseline in Placebo Group | Day 18 | -15.0 score on a scale | Standard Error 1.98 |
| AGN-241751 25mg Two Times Per Day | Part B: Change From Baseline in MADRS Score on Day 11, Day 14, and Day 18 of AGN-241751 Administered Two Times Daily and on Day 21 (7 Days After Completion of Dosing) in Treated Group Compared to Change From Baseline in Placebo Group | Day 21 | -16.5 score on a scale | Standard Error 1.84 |
| AGN-241751 25mg Two Times Per Day | Part B: Change From Baseline in MADRS Score on Day 11, Day 14, and Day 18 of AGN-241751 Administered Two Times Daily and on Day 21 (7 Days After Completion of Dosing) in Treated Group Compared to Change From Baseline in Placebo Group | Day 14 | -15.3 score on a scale | Standard Error 1.82 |
| AGN-241751 25mg Two Times Per Day | Part B: Change From Baseline in MADRS Score on Day 11, Day 14, and Day 18 of AGN-241751 Administered Two Times Daily and on Day 21 (7 Days After Completion of Dosing) in Treated Group Compared to Change From Baseline in Placebo Group | Day 11 | -15.2 score on a scale | Standard Error 1.72 |
| Placebo 2 Times Per Day | Part B: Change From Baseline in MADRS Score on Day 11, Day 14, and Day 18 of AGN-241751 Administered Two Times Daily and on Day 21 (7 Days After Completion of Dosing) in Treated Group Compared to Change From Baseline in Placebo Group | Day 21 | -16.5 score on a scale | Standard Error 1.74 |
| Placebo 2 Times Per Day | Part B: Change From Baseline in MADRS Score on Day 11, Day 14, and Day 18 of AGN-241751 Administered Two Times Daily and on Day 21 (7 Days After Completion of Dosing) in Treated Group Compared to Change From Baseline in Placebo Group | Day 11 | -14.0 score on a scale | Standard Error 1.67 |
| Placebo 2 Times Per Day | Part B: Change From Baseline in MADRS Score on Day 11, Day 14, and Day 18 of AGN-241751 Administered Two Times Daily and on Day 21 (7 Days After Completion of Dosing) in Treated Group Compared to Change From Baseline in Placebo Group | Day 18 | -16.9 score on a scale | Standard Error 1.86 |
| Placebo 2 Times Per Day | Part B: Change From Baseline in MADRS Score on Day 11, Day 14, and Day 18 of AGN-241751 Administered Two Times Daily and on Day 21 (7 Days After Completion of Dosing) in Treated Group Compared to Change From Baseline in Placebo Group | Day 14 | -14.7 score on a scale | Standard Error 1.71 |
Comparison: Change from baseline in treated group compared to change from baseline in placebo group on Day 11. Since this was a phase 1 study, no power calculation was performed. Statistical tests were 2-sided hypothesis tests performed at the 5% level of significance.p-value: 0.43Mixed Models Analysis
Comparison: Change from baseline in treated group compared to change from baseline in placebo group on Day 11. Since this was a phase 1 study, no power calculation was performed. Statistical tests were 2-sided hypothesis tests performed at the 5% level of significance.p-value: 0.59Mixed Models Analysis
Comparison: Change from baseline in treated group compared to change from baseline in placebo group on Day 14, Since this was a phase 1 study no power calculation was performed. Statistical tests were 2-sided hypothesis tests performed at the 5% level of significance.p-value: 0.35Mixed Models Analysis
Comparison: Change from baseline in treated group compared to change from baseline in placebo group on Day 14. Since this was a phase 1 study, no power calculation was performed. Statistical tests were 2-sided hypothesis tests performed at the 5% level of significance.p-value: 0.82Mixed Models Analysis
Comparison: Change from baseline in treated group compared to change from baseline in placebo group on Day 18. Since this was a phase 1 study, no power calculation was performed. Statistical tests were 2-sided hypothesis tests performed at the 5% level of significance.p-value: 0.61Mixed Models Analysis
Comparison: Change from baseline in treated group compared to change from baseline in placebo group on Day 18. Since this was a phase 1 study no power calculation was performed. Statistical tests were 2-sided hypothesis tests performed at the 5% level of significance.p-value: 0.47Mixed Models Analysis
Comparison: Change from baseline in treated group compared to change from baseline in placebo group on Day 21. Since this was a phase 1 study, no power calculation was performed. Statistical tests were 2-sided hypothesis tests performed at the 5% level of significance.p-value: 0.76Mixed Models Analysis
Comparison: Change from baseline in treated group compared to change from baseline in placebo group on Day 21. Since this was a phase 1 study no power calculation was performed. Statistical tests were 2-sided hypothesis tests performed at the 5% level of significance.p-value: 0.99Mixed Models Analysis